bims-supasi Biomed News
on Sulfation pathways and signalling
Issue of 2026–08–09
twelve papers selected by
Jonathan Wolf Mueller, University of Birmingham



  1. Biochim Biophys Acta Rev Cancer. 2026 Aug 03. pii: S0304-419X(26)00146-0. [Epub ahead of print] 189674
      Circulating tumor-derived extracellular vesicles (tdEVs) offer a minimally invasive source of real-time molecular information from cancers. Detection of tdEVs, however, is hindered by their heterogeneity, scarcity, and lack of robust identification markers. Oncofetal chondroitin sulfate (ofCS), a placenta-associated glycosaminoglycan that is commonly re-expressed in cancer, has emerged as a promising, multivalent surface handle to recognize circulating tumor cells and proteoglycans in liquid biopsies. Recent work demonstrates that tdEVs released by diverse cancer cell lines and in plasma from patients with pancreatic cancer expose ofCS. This mini-review evaluates these findings and defines priorities for clinical translation.
    Keywords:  Biomarker; Blood; Cancer; Chondroitin sulfate; Extracellular vesicles; Liquid biopsy; Oncofetal; VAR2
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189674
  2. Fish Shellfish Immunol. 2026 Aug 06. pii: S1050-4648(26)00536-X. [Epub ahead of print] 111632
      Sea cucumber is a high-value marine food that contains characteristic bioactive components, notably saponins and polysaccharides. Strategies promoting their biosynthesis to improve sea cucumber quality are vital for the industry. The impacts of three dietary yeast β-glucans (native β-glucan, ultrasonic-degraded low-molecular-weight β-glucan, and carboxymethylated β-glucan) on the biosynthesis of saponin and fucosylated chondroitin sulfate (FCS) in A. japonicus and the underlying mechanism were investigated. A 28-day feeding trial showed that modified β-glucans improved growth performance and immune responses, as well as elevated the body wall accumulation of saponin and FCS. Mechanistically, modified β-glucans up-regulated the genes involved in the saponin and FCS biosynthesis, including the core mevalonate pathway (hmgcr, mvk, mvd), downstream post-squalene modifications (sqle), and chondroitin backbone biosynthesis (xylt1, chsy1, chpf). Moreover, these β-glucans up-regulated the TLR-MAPK signaling axis genes (tlr, myd88, irak4, traf6, tak1, mkk1, erk, p38) and increased p38/ERK protein abundance and phosphorylation levels. In vivo MAPK inhibition attenuated β-glucan-induced saponin and FCS accumulation and the expression of hmgcr, sqle, xylt1, and chsy1. Our findings reveal that modified β-glucans enhance A. japonicus quality by promoting saponin and FCS biosynthesis in association with the TLR-MAPK signaling axis-mediated immune-metabolic crosstalk.
    Keywords:  Aquatic product quality; Bioactive compounds; Chondroitin biosynthesis pathway; Immune-metabolic crosstalk; Mevalonate pathway
    DOI:  https://doi.org/10.1016/j.fsi.2026.111632
  3. Elife. 2026 Aug 06. pii: RP108925. [Epub ahead of print]14
      Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin-converting enzyme 2 (ACE2) is widely considered the receptor for cell-surface attachment and subsequent cell entry. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment, and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ~6-137 HS molecules projecting 60-410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS-binding agent pixantrone strongly inhibited an authentic pathogen, the SARS-CoV-2 Omicron JN.1 subvariant, from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.
    Keywords:  MINFLUX nanoscopy; SARS-CoV-2; attachment receptor; heparan sulfate; infectious disease; microbiology; virus endocytosis; virus receptor; viruses
    DOI:  https://doi.org/10.7554/eLife.108925
  4. J Infect Chemother. 2026 Aug 06. pii: S1341-321X(26)00144-3. [Epub ahead of print]32(9): 103046
      La Crosse virus (LACV) is a mosquito-borne orthobunyavirus within the California serogroup that primarily causes neuroinvasive disease in pediatric populations in the upper Midwestern, mid-Atlantic, and southeastern states of USA. Despite its substantial impact on public health, no vaccine or effective antiviral treatment has been developed so far. In this study, we investigated the role of the cell-surface heparan sulfate proteoglycan (HSPG) in LACV cell attachment and assessed the in vitro antiviral potential of bovine lactoferrin (bLf), which interacts with both the cell surface molecules and HSPG. Our results demonstrated that HSPG facilitates LACV infection and that bLf inhibits this process in a dose-dependent manner. These observations suggest that the antiviral mechanism of bLf may involve competitive inhibition at HSPG receptor sites, thereby preventing viral attachment to the host cell membrane. This provides further insights into the antiviral activity of bLf against LACV.
    Keywords:  Bovine lactoferrin; Heparan-sulfate proteoglycan; La Crosse virus
    DOI:  https://doi.org/10.1016/j.jiac.2026.103046
  5. Curr Opin Endocrinol Diabetes Obes. 2026 Aug 06.
       PURPOSE OF REVIEW: Adrenal insufficiency is a potentially life-threatening condition requiring timely diagnosis. Baseline morning cortisol remains the initial diagnostic test; however, indeterminate values (3-15 μg/dl) necessitate dynamic testing, which is costly and labor-intensive. This review summarizes recent advances in diagnostic approaches for patients with indeterminate baseline cortisol levels.
    RECENT FINDINGS: Studies support lowering morning cortisol cutoff values to reduce unnecessary cosyntropin testing. Dehydroepiandrosterone sulfate (DHEAS), when age-adjusted and sex-adjusted, may help rule out primary adrenal insufficiency in indeterminate cases. Salivary cortisone has emerged as a practical, home-based screening alternative that circumvents cortisol-binding globulin variability. The insulin tolerance test and overnight metyrapone test remain valuable for central adrenal insufficiency diagnosis, with recent data supporting revised cortisol thresholds.
    SUMMARY: Emerging evidence supports a multimodal diagnostic approach combining baseline cortisol with adjunctive markers such as DHEAS and salivary cortisone. These strategies may reduce reliance on dynamic testing while maintaining diagnostic accuracy, ultimately improving patient convenience and healthcare efficiency.
    Keywords:  adrenal insufficiency; cortisol; cosyntropin stimulation test; dehydroepiandrosterone sulfate; salivary cortisone
    DOI:  https://doi.org/10.1097/MED.0000000000000969
  6. Front Oncol. 2026 ;16 1778726
       Background: Glucocorticoids (GCs) are used to treat multiple pathologies; however, their prolonged use leads to numerous adverse effects. Non-steroidal selective agonists of the glucocorticoid receptor (SEGRAs) have the potential to be a worthy substitute for dexamethasone (DXM). The aim of this study was to compare the effects of SEGRAs and DXM on the cell composition and extracellular matrix of normal brain tissue, with a focus on the acute short-term effects of these drugs.
    Methods: C57Bl/6 mice (n = 28) received an intraperitoneal injection of SEGRA (CpdA or CpdA-03) or DXM after carrageenan-induced paw edema. After 7.5 h, brain tissue was analyzed for neurons and astrocytes by IHC and Western blotting (anti-NF and anti-GFAP, respectively). Expression of proteoglycan (PG) core proteins and heparan sulfate (HS) metabolism-involved genes was determined by RT-PCR. The glycosaminoglycan (GAG) content was determined by dot blot and Alcian blue staining.
    Results: All studied drugs possessed similar anti-edema activity but differed in their effects on brain tissue. Unlike DXM, SEGRAs had no effect on neurofilament (NF) content in the mouse brain. Regarding astrocytes, although all drugs increased astrocyte number and outgrowth, only DXM and CpdA, but not CpdA-03, induced the appearance of a minor (44kDa) GFAP isoform associated with neurocognitive impairment. Neither DXM nor CpdA-03 affected the expression of genes coding PG core proteins and HS biosynthetic enzymes, and only CpdA upregulated the expression of syndecan-3, neurocan, aggrecan, and biglycan (2.5- to 3.5-fold). At the same time, all drugs decreased the content of total (1.5- to 2.8-fold) and sulfated (2- to 3-fold) GAGs, with the least effect observed for CpdA-03.
    Conclusion: Between the two studied SEGRAs, CpdA shows more pronounced effects on the cellular and extracellular components of normal mouse brain tissue compared with DXM. CpdA-03 demonstrated the least effect on brain tissue and may be promising for further development as a less toxic replacement for glucocorticoids.
    Keywords:  brain extracellular matrix; dexamethasone; glial fibrillary acidic protein; glucocorticoid; glycosaminoglycan; heparan sulfate; proteoglycan; selective glucocorticoid receptor agonist
    DOI:  https://doi.org/10.3389/fonc.2026.1778726
  7. Nat Neurosci. 2026 Aug 06.
      Glioma pathophysiology is robustly regulated by interactions with neurons. Key to these interactions is the role of neuroligin-3 (NLGN3), a synaptic adhesion molecule shed in response to neuronal activity that functions as a paracrine factor crucial for glioma growth. Here we elucidate the mechanistic pathway whereby shed NLGN3 interacts with glioma and their normal glial counterparts. NLGN3 binds to chondroitin sulfate proteoglycan 4 (CSPG4, also known as NG2) on both glioma and healthy oligodendrocyte precursor cells (OPCs), facilitating CSPG4 shedding by ADAM10. NLGN3-CSPG4 interactions alter membrane tension, thereby activating mechanotransducers, primarily PIEZO1, leading to membrane depolarization and subsequent ADAM10-mediated CSPG4 shedding. The NLGN3-CSPG4-PIEZO1 pathway maintains OPCs in an undifferentiated, stem-like state and promotes glioma proliferation, underscoring its dual roles in healthy and malignant contexts.
    DOI:  https://doi.org/10.1038/s41593-026-02397-8
  8. Small. 2026 Aug 03. e74968
      Cholecystokinin-8, an octapeptide, is a gut hormone mainly involved in the digestive process and neuromodulation. Over the last four decades, its biological functions have been elucidated and shown to be critically modulated by tyrosine sulfation. Recently, this octapeptide has been identified as a potential biomarker in several tumours. Regrettably, there are no clinical or analytical methods capable of distinguishing between the unsulfated (CCK-8) and sulfated (SO3-CCK-8) forms in controlled media (e.g., saline) or complex biofluids (e.g., human serum). Here, we use an aerolysin nanopore inserted in a lipid-polymer membrane to discriminate them with high specificity and sensitivity at the single-molecule level in both controlled media and complex biofluids, even at low nanomolar concentrations. We found that sulfated and unsulfated CCK-8 generate highly resolutive electrical signatures. Analysis of these signals shows discrimination based on three independent parameters. Using a robust hybrid lipid-coblock membrane, we successfully performed measurements in 20% (v/v) human serum, thereby enabling the identification of peptides differing by a subtle post-translational modification. These results enable reliable discrimination of these biomarkers for diagnostic evaluation.
    Keywords:  PTMs; biofluids; gastric cancer biomarkers; nanopores; peptides
    DOI:  https://doi.org/10.1002/smll.74968
  9. J Steroid Biochem Mol Biol. 2026 Aug 07. pii: S0960-0760(26)00162-7. [Epub ahead of print] 107096
      This mini review addresses the need to draw attention to the existence of an unknown estrogen metabolite, 5α,6α-epoxy-estrone, that was identified recently. The importance of metabolism of the primary steroid hormones from the gonads and adrenal glands has become even more evident in recent years. A recent review on the metabolism of endogenous and exogenous estrogens has revealed its importance in all aspects of estrogen action in women. Its hypothetical structure had been reported earlier but was only recently confirmed by LC-MS/MS. A brief account is given of its discovery using radiolabeled estrone as substrate in incubations with tissues from the reproductive system of the boar. Noteworthy was failure to detect it using nonlabeled substrate; there was no aromatic ring A and no characteristic UV absorption. It was present largely in the steroid conjugated fraction as a sulfate. Studies were made later with the lesser amounts of material in the unconjugated fractions. Brief descriptions of the work and findings include a third oxygen located at C6. Epoxidase action likely formed the hypothesized chemical structure (5α,6α-epoxy-estrone). It was later found that sulfatase activity resulted in only E1, no 5α,6α-epoxy-E1. Therefore identification would have to be done as a sulfate. This was later achieved using LC-MS/MS with stallion jugular blood. It is stressed that no chemical synthesis has been done and without a reference standard there are no data on biological significance. A discussion follows as to methods to address this in human subjects where epoxy-E1 is assuredly present, as reported for several other species.
    Keywords:  Epoxide; Estrone; Radioactive steroids; Stable metabolite; Steroid sulphate
    DOI:  https://doi.org/10.1016/j.jsbmb.2026.107096
  10. Front Immunol. 2026 ;17 1734778
      Myeloid cells play a key role in cancer-associated immunosuppression because their accumulation and reprogramming inhibit antitumor responses and support tumor growth. To modulate their activity, we targeted Fcγ receptors (FcγRs), which are broadly expressed in myeloid subsets. Since low-affinity Fcγ receptor IIb (FcγRIIb) mediates inhibitory signaling, we designed an immunotherapy active at a low dose to limit binding to FcγRIIb while retaining interaction with higher-affinity FcγRs. We engineered an Fc-based fusion protein, whose activity is potentiated by its ability to engage both FcγRs and a coreceptor, Heparan Sulfate Proteoglycan (HSPGs). This immunotherapy, named Fc-T54, combines an HSPG-ligand, named T54, with human IgG1-Fc. Compared with Fc, Fc-T54 displayed superior binding to Fcγ receptor IIa (FcγRIIa), Fcγ receptor IIIa (FcγRIIIa) and enhanced interactions with human leukocytes, including neutrophils, B-lymphocytes, as well as with monocytes, and dendritic cells (DCs) within peripheral blood mononuclear cells. Functionally, Fc-T54 increased monocyte/macrophage and B-cell numbers, reduced neutrophil abundance, and boosted DC activation in both the human and murine systems. Subcutaneous administration of low-dose Fc-T54 - or its murine surrogate - inhibits tumor growth in immune-deserted and immune-excluded mouse models and synergizes with anti-PD-1 therapy in an immune-inflamed model. Tumor microenvironment analysis in the bladder cancer model revealed that the immunotherapy decreased the proportion of granulocytic myeloid-derived suppressor cells while increasing CD8+ T cells and natural killer cells, promoting a microenvironment more prone to tumor control. This FcγR/HSPG-engaging immunotherapy, administered subcutaneously, offers a novel approach to modulate the myeloid compartment and improve outcomes for ICI-resistant, deserted/excluded tumors, and for inflamed tumors when used in combination regimens.
    Keywords:  Fc-gamma receptor; FcγR/HSPG-engaging immunotherapy; dendritic cell activation; heparan-sulfate proteoglycan; highly immunosuppressed tumors; myeloid-targeted immunotherapy
    DOI:  https://doi.org/10.3389/fimmu.2026.1734778
  11. Ren Fail. 2026 Dec;48(1): 2706213
       BACKGROUND: Chronic kidney disease (CKD) is a major global health issue. Cardiovascular events and infections drive mortality in end-stage renal disease via immune dysregulation. The role of T-cell purinergic signaling and its modulation by indoxyl sulfate (IS) in CKD remains unclear.
    METHODS: Male Sprague-Dawley rats underwent 5/6 nephrectomy. The CKD + IS group received daily IS (100 μg/kg, intraperitoneally) for 24 weeks; control group received saline. Samples were collected 2-6 h post-injection. Sepsis was induced via cecal ligation and puncture. Splenic T-cell mRNA cluster of differentiation (CD) 73, CD39, A2A receptor (A2AR), P2X purinergic receptor (P2RX7), nuclear factor kappa-B (NF-κB) was quantified by quantitative real-time polymerase chain reaction. Plasma cytokines, vascular injury markers (asymmetric dimethylarginine (ADMA), intercellular adhesion molecule 1 (ICAM-1)), and myocardial markers (cardiac troponin T (cTnT), B-type natriuretic peptide (BNP)) were measured by enzyme-linked immunosorbent assay. Peripheral purine metabolites (adenosine triphosphate, adenosine diphosphate, adenosine monophosphate, adenosine (ADO)) were analyzed via ultra-high performance liquid chromatography-tandem mass spectrometry. Survival was monitored for 72 h.
    RESULTS: IS exacerbated baseline microinflammation, elevating plasma cytokines (interleukin 2 (IL-2), IL-6, IL-10, IL-17, tumor necrosis factor-alpha (TNF-α)) and T-cell NF-κB. This coincided with disrupted anti-inflammatory purinergic signaling, characterized by downregulated CD73/A2AR and reduced ADO. Post-infection, the CKD + IS group showed profound CD73 suppression and ADO depletion. Despite blunted cytokine surges, this group exhibited aggravated vascular and myocardial injury (elevated ADMA, ICAM-1, cTnT, BNP) and significantly higher 72-hour mortality.
    CONCLUSIONS: Indoxyl sulfate disrupts the T-cell CD73/ADO axis, promoting basal microinflammation while impairing anti-infective immunity and exacerbating organ damage during sepsis. Targeting the IS-CD73-ADO pathway offers a therapeutic strategy for restoring immune homeostasis in uremia.
    Keywords:  CD73; Chronic kidney disease; T cell dysfunction; adenosine; indoxyl sulfate
    DOI:  https://doi.org/10.1080/0886022X.2026.2706213
  12. Int J Biol Macromol. 2026 Aug 01. pii: S0141-8130(26)03820-1. [Epub ahead of print]378 153874
      3D-printed gelatin scaffolds are widely explored for bone regeneration due to their excellent biocompatibility and biodegradability, yet their clinical translation is severely hindered by several inherent defects, including weak mechanical stability, fast in vivo biodegradation, limited osteogenic capability, and the absence of anti-infective functions. Globally, it remains a key challenge in bone tissue engineering to develop integrated scaffold systems that simultaneously satisfy mechanical matching, long-term biological activity, and anti-pathogenic requirements. To address this challenge, a multifunctional CHm/PCA/Cu2+/ε-PL@Gel-OCS scaffold with enhanced mechanical properties, outstanding antibacterial, anti-inflammatory, pro-vascularization and osteogenic activities was developed via cryogenic 3D printing of a gelatin (Gel)/oxidized chondroitin sulfate (OCS) composite ink loaded with chitosan microspheres surface-functionalized by protocatechuic aldehyde (PCA), copper ions (Cu2+) and ε-polylysine (ε-PL). Scanning electron microscopy and energy-dispersive X-ray analysis confirmed uniform dispersion of the microspheres and sustained release of therapeutic agents as the scaffold degraded. Rheological and mechanical testing demonstrated excellent print fidelity, interconnected porosity (161 ± 37 μm pores), and compressive strengths (100-200 MPa) suitable for cortical bone repair. Such porous structure and mechanical performance are highly compatible with human cortical bone microenvironment, which facilitates cell infiltration, nutrient exchange and mechanical load bearing. In vitro release studies revealed a sequential sustained release profile (OCS > Cu2+ > ε-PL), ensuring a sustainable osteogenic, angiogenic, anti-inflammatory and antibacterial activity. The scaffold achieved 100% bactericidal efficiency against both Staphylococcus aureus and Escherichia coli, suppressed protein denaturation (anti-inflammation), and promoted neovascularization in a chick chorioallantoic membrane assay. Biocompatibility assays using MC3T3-E1 osteoblasts showed enhanced cell adhesion, proliferation, and live/dead viability over 5 days. Osteogenic potential was significantly elevated on the multifunctional scaffold, as evidenced by time-dependent increases in ALP activity, mineral deposition (Alizarin Red S), and upregulated expression of ALP, RUNX2, OPN, and OCN genes compared with Gel and Gel-OCS controls. Taken together, our cryogenic 3D-printed Gel-OCS scaffold incorporating PCA/Cu2+/ε-PL-functionalized chitosan microspheres provides a single-step, customizable platform that combines robust mechanical properties with multi-modal therapeutic functionalities. Different from conventional single-function bone scaffolds reported in most international studies, this multi-component synergistic design successfully realizes the integration of mechanical reinforcement, antibacterial, anti-inflammatory, vascularization and osteogenesis functions in one system. These promising preclinical results highlight a novel therapeutic strategy for bone defect regeneration, it solves the common bottlenecks of traditional gelatin-based bone scaffolds, provides a feasible and universal fabrication strategy for high-performance multifunctional bone repair materials, and offers new insights for the global development and clinical translation of 3D-printed bone tissue engineering scaffolds.
    Keywords:  3D printing; Anti-infective capability; Functionalized chitosan microspheres; Multifunctional gelatin scaffold; Osteogenic activity; Pro-angiogenic property
    DOI:  https://doi.org/10.1016/j.ijbiomac.2026.153874